Fitch Reaffirms Bristol-Myers Squibb Ratings
NEW YORK (AP) ¿ Fitch Ratings affirmed Bristol-Myers Squibb Co.'s ratings Thursday and said the outlook for the company remains "Stable," citing moves by Bristol-Myers to offset the potential loss of future revenue as blockbuster drugs lose patent protection.
Earlier Thursday, the New York-based company said it completed its initial tender offer for shares of Medarex Inc., a biotechnology rival it agreed to buy for $2.1 billion earlier this summer. The company said 87.7 percent of Medarex stock, or a total of 119 million shares, were tendered.
Fitch reaffirmed 'A+', or investment-grade, ratings for Bristol-Myers' long-term issuer default rating, senior unsecured debt, and bank loan. The ratings apply to about $6.4 billion of outstanding debt.
Fitch said Bristol-Myers has streamlined its product portfolio and mentioned the potential for sales of the diabetes drug Onglyza. The company will likely see sales of its high blood pressure drug Avapro and blood-thinner Plavix fall after 2011 as patents expire. That will open the door to generic competition, cutting into revenue for both drugs."Fitch believes that operational strength, coupled with a solid intellectual property position, will improve financial metrics in the intermediate term, as Bristol-Myers Squibb is relatively free of intellectual property losses in the U.S.," the ratings agency said in a statement. Shares of Bristol-Myers fell 15 cents to $22.76 in midday trading.
Select the service that is right for you!COMPARE ALL SERVICES
Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.
- $2.5+ million portfolio
- Large-cap and dividend focus
- Intraday trade alerts from Cramer
- Weekly roundups
Access the tool that DOMINATES the Russell 2000 and the S&P 500.
- Buy, hold, or sell recommendations for over 4,300 stocks
- Unlimited research reports on your favorite stocks
- A custom stock screener
- Upgrade/downgrade alerts
Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.
- Diversified model portfolio of dividend stocks
- Alerts when market news affect the portfolio
- Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.
- Real Money + Doug Kass Plus 15 more Wall Street Pros
- Intraday commentary & news
- Ultra-actionable trading ideas
Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.
- 100+ monthly options trading ideas
- Actionable options commentary & news
- Real-time trading community
- Options TV